SciSparc Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

SciSparc has been growing earnings at an average annual rate of 11.8%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 88.7% per year.

Anahtar bilgiler

11.8%

Kazanç büyüme oranı

93.5%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi6.0%
Gelir büyüme oranı88.7%
Özkaynak getirisi-61.4%
Net Marj-177.9%
Son Kazanç Güncellemesi31 Dec 2023

Yakın geçmiş performans güncellemeleri

Güncelleme yok

Recent updates

SciSparc to acquire an American food supplements and cosmetics brand in ~$20M deal

Aug 15

SciSparc board of directors to promote buyback program of up to $1M

Jul 06

SciSparc completes development of SCI-110 to treat tourette syndrome

Jun 29

Gelir ve Gider Dağılımı

SciSparc nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqCM:SPRC Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
31 Dec 233-562
30 Sep 233-262
30 Jun 233062
31 Mar 232-162
31 Dec 221-373
30 Sep 221-663
30 Jun 220-953
31 Mar 220-752
31 Dec 210-642
30 Sep 210-532
30 Jun 210-331
31 Mar 210-321
31 Dec 200-321
30 Sep 200-421
30 Jun 200-522
31 Mar 200-422
31 Dec 190-522
30 Sep 190-531
30 Jun 190-542
31 Mar 190-962
31 Dec 180-643
30 Sep 180-853
30 Jun 180-753
31 Mar 180-853
31 Dec 170-642
30 Sep 170-431
30 Jun 170-321
31 Mar 170-211
31 Dec 160-211
30 Sep 160-231
30 Jun 160-320
31 Mar 160-320
31 Dec 150-310
30 Sep 150-310
30 Jun 150-210
31 Mar 150-210
31 Dec 140-210
30 Sep 140-211
30 Jun 140-211
31 Mar 140011

Kaliteli Kazançlar: SPRC is currently unprofitable.

Büyüyen Kar Marjı: SPRC is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: SPRC is unprofitable, but has reduced losses over the past 5 years at a rate of 11.8% per year.

Büyüme Hızlandırma: Unable to compare SPRC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: SPRC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).


Özkaynak Getirisi

Yüksek ROE: SPRC has a negative Return on Equity (-61.36%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin